Strengths and limitations of the six-minute-walk test: A model biomarker study in idiopathic pulmonary fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 9, 2011, Pages 1122-1124

  Heresi, Gustavo A ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

CLINICAL EFFECTIVENESS; EDITORIAL; FIBROSING ALVEOLITIS; FUNCTIONAL STATUS; HUMAN; LUNG FUNCTION TEST; MEASUREMENT ERROR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SIX MINUTE WALK TEST; WALKING;

BIOLOGICAL MARKERS; EXERCISE TEST; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MODELS, BIOLOGICAL; WALKING;

EID: 79955501249     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201012-2079ED     Document Type: Editorial

References (23)

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
2. Cooper KH. A means of assessing maximal oxygen intake. correlation between field and treadmill testing. JAMA 1968;203:201-204.
3. McGavin CR, Gupta SP, McHardy GJ. Twelve-minute walking test for assessing disability in chronic bronchitis. BMJ 1976;1:822-823.
4. McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: Comparison of estimates of exercise performance in respiratory disease. BMJ 1978;2:241-243. (Pubitemid 8382018)
5. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) 1982;284:1607-1608. (Pubitemid 12105148)
6. Elpern EH, Stevens D, Kesten S. Variability in performance of timed walk tests in pulmonary rehabilitation programs. Chest 2000;118:98-105. (Pubitemid 30485496)
7. American Thoracic Society. ATS Statement: guidelines for the six-minute- walk test. Am J Respir Crit Care Med 2002;166:111-117.
8. Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Califf RM, O'Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001;88:987-993. (Pubitemid 33042609)
9. Enfield K, Gammon S, Floyd J, Falt C, Patrie J, Platts-Mills TA, Truwit JD, Shim YM. Six-minute walk distance in patients with severe endstage copd: Association with survival after inpatient pulmonary rehabilitation. J Cardiopulm Rehabil Prev 2010;30:195-202.
10. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492. (Pubitemid 30129457)
11. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-809. (Pubitemid 44511662)
12. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
13. Lee WT, Peacock AJ, Johnson MK. The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. Eur Respir J 2010;36:1294-1301.
14. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788. (Pubitemid 34925627)
15. du Bois RM, Weycker D, Albera C, Bradford WC, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, et al. Six-minute walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-1237.
16. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383. (Pubitemid 34260746)
17. Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005;2:63-67. (Pubitemid 40776225)
18. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431-440. (Pubitemid 19105891)
19. van den Blink B, Wijsenbeek MS, Hoogsteden HC. Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2010;23:515-520.
20. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, Erzurum SC, Dweik RA. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008;295:L789-L799.
21. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, et al. Exhaled nitric oxide in pulmonary diseases: A comprehensive review. Chest 2010;138:682-692.
22. Heresi GA, Aytekin M, Newman J, Dweik RA. Cxc-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: Marker of improved survival. Lung 2010;188:191-197.
23. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:661-668.